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Abstract
Proximal 6q (6q11-q15) deletions are extremely rare and little is known about their phenotypic consequences. Since parents
and caregivers now use social media to seek information on rare disorders, the Chromosome 6 Project has successfully
collaborated with a Facebook group to collect data on individuals worldwide. Here we describe a cohort of 20 newly
identiﬁed individuals and 25 literature cases with a proximal 6q deletion. Microarray results and phenotype data were
reported directly by parents via a multilingual online questionnaire. This led to phenotype descriptions for ﬁve subregions of
proximal 6q deletions; comparing the subgroups revealed that 6q11q14.1 deletions presented less severe clinical
characteristics than 6q14.2q15 deletions. Gastroesophageal reﬂux, tracheo/laryngo/bronchomalacia, congenital heart defects,
cerebral defects, seizures, and vision and respiratory problems were predominant in those with 6q14.2q15 deletions.
Problems related to connective tissue (hypermobility, hernias and foot deformities) were predominantly seen in deletions
including the COL12A1 gene (6q13). Congenital heart defects could be linked to deletions of MAP3K7 (6q15) or TBX18
(6q14.3). We further discuss the role of ten genes known or assumed to be related to developmental delay and/or autism
(BAI3, RIMS1, KCNQ5, HTR1B, PHIP, SYNCRIP, HTR1E, ZNF292, AKIRIN2 and EPHA7). The most inﬂuential gene on
the neurodevelopmental phenotype seems to be SYNCRIP (6q14.3), while deletions that include more than two of these
genes led to more severe developmental delay. We demonstrate that approaching individuals via social media and collecting
data directly from parents is a successful strategy, resulting in better information to counsel families.
Introduction
Deletions of the proximal part of the long arm of chromo-
some 6, extending from 6q11 to 6q15, are rare and infor-
mation on the related clinical phenotypes is scarce. The
largest review to date was published by Hopkin et al. [1] in
1997; it describes 14 individuals with proximal 6q
deletions, diagnosed by conventional cytogenetic methods.
These individuals presented variable degrees of cognitive
impairment and minor dysmorphisms: epicanthic folds,
short nose with broad nasal tip, anteverted nares, long
philtrum and thin upper lip. Pes planus, joint instability,
hypermobility, cardiac anomalies, and umbilical and ingu-
inal hernias were also reported. However, the deletions in
that study covered different subregions of proximal 6q and
they did not all overlap, therefore the shared clinical fea-
tures in their cohort may not always be related to the same
deleted proximal 6q segment.
Thanks to the widespread use of microarray techniques,
the breakpoint estimation of deletions has become more
precise and reproducible, allowing easy and reliable com-
parison of microarray results from all over the world. In
contrast, the objective and precise gathering of phenotypic
information is much more complicated. The availability of
such information in international databases like ECARUCA
(http://www.ecaruca.net) [2] and DECIPHER (https://
decipher.sanger.ac.uk) depends on the time and
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willingness of doctors to submit information. As a result,
only a minority of rare cases are being collected and the
clinical information in these databases is often incomplete.
We have successfully used social media to gain more
knowledge on the 6q11-q15 deletion phenotypes. Patients
and parents of children with rare disorders increasingly seek
information online and share experiences via patient support
groups on social media [3]. Facebook, the largest social
network in the world, has a chromosome 6 patient support
group, with which we started to collaborate in 2013. Via this
group, we were able to collect detailed phenotypic infor-
mation directly from parents of individuals with a proximal
6q deletion. Parents and patients were invited to join the
Chromosome 6 Project via Facebook and Twitter. The
project enabled parents to submit detailed information on
their child via an online interactive questionnaire, which was
made available in seven different languages. This allowed us
to perform genotype–phenotype studies on 20 newly iden-
tiﬁed individuals, in combination with 25 cases described in
the literature. Clinical information and a microarray result
were available for all 45 cases. Our approach led to a
detailed description of the phenotypic effects of proximal 6q
deletions and to the identiﬁcation or conﬁrmation of several
candidate genes for speciﬁc clinical features.
Methods
Our new cohort was recruited through social media. Since
parents provided the clinical information, we have called
this our parent cohort. A second group of patients was
extracted from the literature (literature cohort).
Parent cohort
Individuals were informed about the project via Facebook
(Chromosome 6 Facebook group), Twitter (@C6study) and
our website (https://www.chromosome6.org). Patients or
their legal representatives could participate in our research
by signing up via our secure website. Inclusion criteria were
an isolated chromosome 6 aberration and the availability of
a microarray report. Participants received a personal
account for the online Chromosome 6 Questionnaire and we
obtained their informed consent before they started ﬁlling it
in. The accredited Medical Ethics Review Committee of the
University Medical Centre Groningen waived full ethical
evaluation because, according to Dutch guidelines, no
ethical approval is necessary if medical information that
was already available is used anonymously and no extra
tests have to be performed.
Microarray reports were uploaded within the secure
environment as part of the sign-up procedure. Genotype
data was stored in the Chromosome 6 database and double-
checked, after which the original reports were destroyed.
The microarray analyses were performed in diagnostic
laboratories, using different platforms. The microarray
results were converted to GRCh37/hg19 with the UCSC
LiftOver Tool and visualised using the UCSC genome
browser (http://genome.ucsc.edu). For the present study, we
selected participants with a deletion starting in the region
6q11 to 6q15 and not extending beyond 6q16.
Phenotype information was collected via the Chromo-
some 6 Questionnaire, which was available in English,
Dutch, German, French, Italian, Spanish and Portuguese,
and constructed with the MOLGENIS toolkit [4]. The
questionnaire can only be accessed via a personal account
and all answers are automatically stored in a secure envir-
onment. The questionnaire contains 132 closed main
questions on the pregnancy, birth, congenital abnormalities,
relevant dysmorphic features, development, behaviour and
health of the child. Questions are only shown when
applicable to the participant, based on their age, gender and
previously answered questions.
Clinical photographs were collected once written consent
was given and were stored on a different server to the
database.
Data collected from individuals in the parent cohort was
submitted to the ECARUCA database (http://www.ecaruca.
net) [2] Id’s 5307, 5308 and 5310–5327.
Literature cohort
Case reports involving proximal 6q deletions were collected
using PubMed and the following search criteria: (deletion or
monosomy) and (6q11 or 6q12 or 6q13 or 6q14 or 6q15 or
proximal 6q). Only publications reporting microarray
results or comparable detailed breakpoint analysis were
included. Clinical information was extracted from the
reports using the online Chromosome 6 Questionnaire in
order to have as much identical information in the same
database as possible.
Data analysis
All clinical features and behavioural characteristics were
classiﬁed as present, absent or unknown, and presented as
present/known. The developmental delay (intelligent quo-
tient (IQ)) was categorised as normal (>85), borderline
(70–85), mild (50–70), moderate (30–50) or severe (<30)
delay. This was based on formal IQ tests or, if these were
not available, the mean of the developmental questions for
the milestones ‘walking independently’ and ‘using two-
word sentences’. The developmental quotients were calcu-
lated as the 90th centile of population age of achievement
for that milestone divided by the age of achievement in the
participant, times 100.
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Clinical features were described for the whole group as
well as for subgroups, as depicted in Fig. 1—A: deletions of
6q11q13 extending proximally to 72.5 Mb (calculated
from 6pter) (n= 11); (B) deletions of 6q13q14.1 in the
region 72.5–84.5 Mb (n= 12); (C) deletions of 6q14.2q14.3
in the region 81–88.5 Mb (n= 8); and (D) larger
deletions of 6q14.2q15 extending from 81–95Mb (n= 8).
The remaining deletions, subgroup R, were large
deletions of 6q12q15 overlapping with two or more of the
other subgroups A–D (n= 6). The gene content for each
subgroup was studied taking into account the haploinsufﬁ-
ciency (HI) and loss-of-function intolerance (pLI)
scores. The HI score is deﬁned as the predicted probability
that a gene is more likely to exhibit HI (0–10%),
or more likely not to exhibit HI (90–100%) based on dif-
ferences in characteristics between known haploinsufﬁcient
and haplosufﬁcient genes (https://decipher.sanger.ac.uk)
[5]. The pLI score represents the probability that a
gene is extremely intolerant of loss-of-function variation
(pLI ≥0.9). Genes with scores ≤0.1 are loss-of-function-
tolerant. This score is based on protein-truncating variants
in the ExAC database (http://exac.broadinstitute.org) [6].
We also investigated whether a smallest region of deletion
overlap (SRO) could be deﬁned for speciﬁc clinical
features.
Results
Participant characteristics and genotypes
The online questionnaire was made available in March 2016
and since then 125 parents have registered for an account
and uploaded the microarray results of their child. Up to
September 2017, 45 parents had completed and submitted
the questionnaire. Of these, 20 individuals (13 males and 7
females) had a proximal 6q deletion and could be included
in our parent cohort. We further compiled a cohort of 25
literature cases (12 males and 13 females) from 13 pub-
lished papers [7–19]. The median age (years; months) of
individuals in the parent cohort was 5; 5 (range 0; 1–24;
11), and in the literature cohort was 5; 0 (range 0; 2–22; 0).
In all individuals the breakpoints were deﬁned by
microarray except for four literature cases [11] in whom the
breakpoints were accurately deﬁned by dual-colour FISH
analysis using bacterial artiﬁcial chromosome clones.
Although we excluded individuals with a concomitant
aberration of another chromosome, we tolerated some small
additional rearrangements based on their size and gene
content (see supplementary Table S1 for details and moti-
vation). All individuals were assigned to one of the ﬁve
subgroups. Figure 1 visualises the deletions, showing the
Fig. 1 Overview of all proximal 6q deletions. Deletions in the region
of 6q11-q15 are shown for our parent cohort (black bar) and literature
cohort (grey bar), and are divided into ﬁve subgroups (A–R). A:
deletions of 6q11q13 extending proximally to 72.5 Mb (calculated
from 6pter); B: deletions of 6q13q14.1 in the region 72.5–84.5Mb; C:
deletions of 6q14.2q14.3 in the region 81–88.5Mb; and D: larger
deletions of 6q14.2q15 extending from 81–95Mb. Deletions in
subgroup (R) were large deletions of 6q12q15 overlapping with two or
more of the other subgroups A–D. The deletions are visualised using
the UCSC genome browser (https://genome.ucsc.edu). Patient Id116
also has a partial duplication of 6q14.1 (indicated by a white bar). The
literature cases were derived from 13 reports [7–19]. See supple-
mentary Table S1 for details
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overlap between the different subgroups. The main geno-
type characteristics of the subgroups are summarised in
Table 1 (see supplementary Table S1 for details).
Phenotypes
Phenotype information is summarised in Table 2 (see
supplementary Table S2 for details) and clinical photo-
graphs are shown in Fig. 2. Developmental information is
given in Table 3 and visualised in Fig. 3 and S1. Common
dysmorphic and congenital abnormalities were large size—
(36%) and/or abnormal shape (44%) of the head, brain
abnormalities (50%), dysplastic ears (60%), cardiac defects
(39%), kidney abnormalities (47%), abdominal wall hernias
(52%), abnormal genitals in boys (67%), vertebral column
abnormalities (41%) and joint hyperlaxity (53%). Clinical
complications that were most often reported were feeding
problems (88%) and gastroesophageal reﬂux (55%),
dental problems (50%), vision problems (62%), recurrent
infections (70%) and hypotonia (76%). The majority of the
individuals was described as being social (60%)
with behavioural problems (68%) most often reported
within the autism spectrum. Developmental delay was seen
in all but two participants, child Id057 (subgroup A) and
child Id019 (subgroup B), (Fig. S1), who had developed
normally when seen at the age of 5 and 3; 8 years,
respectively.
Subgroup A (6q11q13) was mostly characterised by the
following dysmorphisms and congenital malformations:
dysplastic ears (4/8), kidney abnormalities (7/10), abnormal
genitals in boys (3/4), umbilical hernia/omphalocele (4/8),
syndactyly of the toes (5/8) and hypermobility of the joints
(6/10). Clinical problems that were most frequently
encountered were dental problems (3/5), feeding problems
(6/7) often requiring tube feeding (4/7), recurrent infections
(3/5), hypotonia (7/10) and postural problems of the ver-
tebral column (4/7). Developmental delay was mostly mild
and most children were described as being social (5/8).
In subgroup B (6q13q14.1), we observed dysplastic outer
ears (6/8), abnormal genitals in boys (4/5), umbilical hernias
(7/10), positional foot deformity (5/10) and hypermobility
of the joints (5/10). Clinical problems that were most fre-
quently reported were: feeding problems (3/4), short stature
(3/8) and hypotonia (8/10). Developmental delay was
mostly borderline to moderate. Most children were descri-
bed as social (5/7), however, some behavioural problems
were also reported (3/5).
A distinction was made between subgroups C (q14.2q14.3)
and D (q14.2q15) based on the size of the deletion (Fig. 1).
Individuals in subgroups C and D had deletions that over-
lapped. Remarkably, the individuals in subgroup C were
identically effected for most features compared to those in
subgroup D, indicating that the region q14.2q14.3 had the
strongest inﬂuence on the phenotype. This is exempliﬁed for
developmental delay in supplementary Fig. S1, showing that
moderate to severe developmental delay is seen in the majority
of individuals over age 2 years with a deletion in this region.
Subgroups C and D together (6q14.2q15) were mostly char-
acterised by macrocephaly (8/16), brain abnormalities (7/12,
especially ventriculomegaly/hydrocephalus and corpus callo-
sum abnormalities), dysplastic outer ears (6/11), congenital
heart defects (7/14), kidney abnormalities (4/11) and abnormal
genitals in boys (3/7). Medical problems seen in both groups
were: vision problems (10/12), gastroesophageal reﬂux (6/8),
constipation (4/8), recurrent infections (7/10), hypotonia (10/
14) and seizures (5/10). Feeding difﬁculties (10/11) were
frequently seen, but tube feeding was required more often in
subgroup D. Epilepsy (3/6) and tracheo/laryngo/bronchoma-
lacia (3/7) was only seen in subgroup D. Most children were
described as being social, but behavioural problems were
common (6/7), especially autism spectrum disorder, hyper-
activity and self-harming behaviour.
As expected, individuals in subgroup R with larger
deletions overlapping the smaller subgroups A–D were
more severely affected. The most commonly reported
congenital abnormalities were brain abnormalities and





Size median (range) Mb No. of OMIM genes
median (range)
No. of OMIM disease
genes median (range)
A: q11q13 (n= 11) 5/6 3; 6 (0; 1–20; 0) 14.71 (8.11–20.19) 31 (12–49) 11 (5–17)
B: q13q14.1 (n= 12) 4/8 5; 9 (0; 9–10; 0) 9.48 (3.26–13.01) 31 (9–47) 11 (3–16)
C: q14.2q14.3 (n= 8) 3/5 10; 6 (2; 11–19; 0) 4.73 (0.02–9.05) 23 (2–36) 8 (1–11)
D: q14.2q15 (n= 8) 6/2 6; 7 (0; 3–24; 11) 11.73 (6.43–23.88) 40 (19–61) 9 (3–14)
R: q12q15 (n= 6) 2/4 1; 2 (0; 2–6; 6) 24.95 (19.35–28.27) 76 (54–80) 20 (12–22)
Total: q11q15 20/25 5; 5 (0; 1–24; 11) 11.19 (0.02–28.27) 32 (2–80) 11 (1–22)
Genotype characteristics for subgroups A, B, C, D and R, as represented in Fig. 1. The number (median and range) of all OMIM genes and the
OMIM disease-related genes within the deletions are given (https://www.omim.org/)
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congenital heart defects. Medical problems were low birth
weight, feeding difﬁculties, nystagmus, hearing impairment,
recurrent infections, hypotonia, hypermobility and epilepsy.
The severity of developmental delay was only known for
two individuals, while behaviour was described as social
and hyperactive.
Table 2 Overview of most prominent characteristics seen in individuals with proximal 6q deletions
Characteristics Total (n= 45) A (n= 11) B (n= 12) C (n= 8) D (n= 8) R (n= 6)
Sex (male/female) 25/20 5/6 8/4 7/1 3/5 2/4
Complicated delivery 18/30 3/7 5/7 6/7 3/3 1/6
Birth weight (<p10) 9/39 0/11 2/8 2/6 2/7 3/6
Short stature (<p10) 10/36 1/9 3/8 4/8 1/6 1/5
Small head circumference (<p10) 3/44 3/11 0/12 0/8 0/8 0/5
Large head circumference (>p90) 16/44 2/11 3/12 5/8 3/8 3/5
Abnormal skull shape 11/25 2/6 4/7 2/4 1/5 2/3
Brain abnormalities on MRI or CT 15/30 2/6 1/6 4/5 3/7 5/6
Ventriculomegaly/hydrocephaly 8/30 1/6 1/6 4/5 1/7 2/6
Vision problems 16/26 2/5 1/6 6/6 4/6 3/3
Nystagmus 7/24 0/5 1/5 2/4 1/7 3/3
Coloboma 2/24 0/5 0/5 0/5 1/6 1/3
Cataract 3/24 0/5 0/5 2/5 0/6 1/3
Dysplastic outer ear 18/30 4/8 6/8 3/4 3/7 2/3
Mild-moderate hearing impairment 6/25 1/5 2/5 1/6 0/6 2/3
Dental problems 10/20 3/5 1/4 3/4 1/5 2/2
Feeding difﬁculties 23/26 6/7 3/4 5/6 5/5 4/4
Requiring tube feeding 12/26 4/7 1/4 1/6 3/5 3/4
Gastroesophageal reﬂux 11/20 1/5 1/4 3/3 3/5 3/3
Constipation 9/20 2/5 2/4 2/3 2/5 1/3
Congenital heart defect 11/28 0/5 1/5 4/6 3/8 3/4
Atrial septal defect 5/28 0/5 0/5 1/6 2/8 2/4
Tracheo/laryngo/bronchomalacia 6/23 1/5 0/4 0/3 3/7 2/4
Recurrent infections 16/23 3/5 2/4 3/4 4/6 4/4
Kidney abnormality 15/32 7/10 2/7 1/4 3/7 2/4
Abnormal genitals in boys 12/18 3/4 4/5 3/4 0/3 2/2
Inguinal or umbilical hernia 17/33 4/8 8/10 2/5 1/6 2/4
Vertebral column abnormalities 11/27 4/7 1/5 4/6 0/5 2/4
Triphalangeal thumb 2/37 1/10 0/9 0/7 0/6 1/5
Pes planus 6/34 3/8 1/10 1/7 1/6 0/3
Positional foot deformity 7/34 2/8 4/10 0/7 1/6 0/3
Hypermobility of the joints 18/34 6/10 5/10 0/3 1/5 6/6
Hypotonia 28/37 7/10 8/10 5/7 5/7 3/3
Hypertonia/spasticity 5/24 1/7 0/4 1/4 1/6 2/3
Torticollis 5/22 2/6 1/4 1/4 0/6 1/2
Seizures/epilepsy 8/27 0/7 2/8 1/4 3/6 2/2
Developmental delay (Table 3) 38/40 9/10 11/12 8/8 7/7 3/3
Social behaviour 15/25 5/8 5/7 3/4 0/4 2/2
Behavioural problems 19/28 3/8 3/5 7/8 5/5 1/2
Autism spectrum disorder 13/28 3/8 1/5 4/8 5/5 0/2
Hyperactivity 7/28 0/8 1/5 3/8 2/5 1/2
Self-harming 6/28 0/8 1/5 4/8 1/5 0/2
Clinical features in this table were selected based on their clinical signiﬁcance and prevalence. For a more detailed overview, see Supplementary
table S2
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Smallest regions of overlap
We investigated whether SROs could be deﬁned
for the most frequent clinical characteristics listed in
Table 2 (data not shown). This was used to
construct the phenotype–genotype map (Fig. 4) and to
discuss the candidate genes involved (Discussion). Exam-
ples are given in supplementary Figs. S2 and S3 for
connective tissue-related problems and congenital heart
defects, respectively.
Positional foot deformity was present in seven indivi-
duals, of whom six had overlapping deletions with an SRO
of 4.27Mb (72,597–76,869 kb) that includes the candidate
gene COL12A1 (collagen type XII alpha 1 chain,
MIM*120320). Other problems frequently seen in indivi-
duals with this gene deletion were hernias of the abdominal
wall, hyperlaxity and scoliosis (Fig. S2).
Congenital heart defects were seen in 11 patients, of
whom six had a deletion of the known cardiac-related
gene MAP3K7 (mitogen-activated protein kinase 7,
MIM*602614). Four other patients had an overlapping
deletion with an SRO of 3.41Mb (location 84,326–87,736
kb) that includes the candidate gene TBX18 (T-box 18,
MIM*604613) (Fig. S3). The 11th patient had a deletion
breakpoint that was 194 kb proximal of TBX18.
For the multi-factorial features of developmental delay
and autism spectrum disorder, it was difﬁcult to deﬁne
precisely which part of proximal 6q contributed most to the
phenotype. We therefore depicted the deletions by category
(normal/borderline/mild/moderate/severe for developmental
delay and present/absent for autism) together with the genes
known or discussed to be related to these features (sup-
plementary Figs. S1 and S4). As shown in Table 3, devel-
opmental delay was mostly mild to moderate in subgroups
A and B, and moderate to severe in subgroup C+D. The
milestones ‘walking independently’ and ‘using two-word
sentences’ are visualised in Fig. 3. The severity of devel-
opmental delay could not be related to a more speciﬁc
location or to the length of the deletion (supplementary Fig.
S1).
Discussion
The Chromosome 6 Project aims to achieve a better
understanding of the clinical effect of the many different
chromosome 6 abnormalities. Here we report our ﬁndings
for the rare 6q deletions in the region 6q11 to 6q15. The
phenotypic effect of a deletion is not the simple addition of
the HI effects of the genes within the deleted segment. A
Fig. 2 Clinical photographs of
individuals with a proximal 6q
deletion. Photographs of patients
in subgroups A–D. Subgroup A:
patient Id123 (A1) at age
22 months, patient Id065 (A2) at
age 7 years, patient Id057 (A3)
at age 18 months. Subgroup B:
patient Id058 (B1) at age 8
years, patient Id019 (B2) at age
7 years, patient Id011 (B3) at
age 5 years. Subgroup C: patient
Id125 (C1) at age 2; 11 years,
patient Id028 (C2) at age 8
years, patient Id056 (C3) at age
2; 5 years. Subgroup D: patient
Id007 (D1) at age 8 years,
patient Id044 (D2) at age 3
years, patient Id067 (D3) at age
22 years. Written consent was
given to the authors to publish
the patients’ photos
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deletion of multiple genes may result in a more complex
mitigating or reinforcing effect of the under-represented
proteins. Moreover, deletion of non-coding stretches of
DNA may also affect the phenotype. Thus, it seems best to
learn about the clinical effect of deletions by collecting
information on individuals with such deletions. Since
genetic phenotypes show much inter-individual variation,
even when exactly the same gene or chromosome segment
is involved, we need information on as many individuals as
possible to gain a reliable picture of the effects of a speciﬁc
chromosome aberration.
Notwithstanding the limitations mentioned above,
knowing the gene content of a deletion, especially of genes
with a known HI effect, may help to better understand the
phenotype. Certain genes may even have direct clinical
implications, for example, the deletion of a tumour-
suppressor gene leading to an increased risk for cancer
and requiring tumour screening. Other genes may be asso-
ciated with an increased risk for congenital malformations
and may thus direct clinical management when known to be
deleted. Most genes, however, do not have a known HI
effect, or only when they are affected on both alleles, and
many small deletions are only considered ‘risk factors’, ie,
are associated with an increased risk for learning problems,
intellectual disability or behavioural problems, thereby
stressing the multi-factorial nature of the phenotype.
In this discussion, we will relate the clinical phenotypes
seen in our cohort to what is already known about the genes
involved in the deletions. An overview of the genes within
the 6q11-6q15 region and with a HI score HI <50% (https://
decipher.sanger.ac.uk) is given in Table S3, together with
their loss-of-function intolerance score pLI (http://exac.broa
dinstitute.org).
Analysis of deletion subgroups
We collected detailed information on 20 newly identiﬁed
individuals, who were approached via social media, and
studied 25 literature cases. The subgroups showed
considerable genetic overlap (especially subgroups A
and B), while subgroup C deletions are smaller but
almost fully overlap with subgroup D deletions (Fig. 1).
The more proximal subgroups A and B presented
fewer and less severe clinical characteristics than the more
distal subgroups C and D. The individuals in subgroup R,
with the larger deletions, were most severely
affected (Table 2). The clinical characteristics of high
medical concern, such as gastroesophageal reﬂux,
tracheo/laryngo/bronchomalacia, congenital heart defects,
cerebral defects, seizures, and vision and respiratory
problems were predominant in the more distal subgroups, C
and D. However, renal problems—mostly hydronephrosis
—occurred more often in subgroup A (7/10 individuals),
while hypermobility was seen in 6/10 and 5/10
individuals of subgroups A and B, respectively.
Behavioural characteristics, such as autistic behaviour,
hyperactivity and self-harming were more often seen in
subgroups C and D (12/13) than in subgroups A and B (6/
13). Most literature reports on deletions of 6q14q15 have
focused on early-onset obesity, which was not a common
problem in our cohort. Cleft palate [10] and syndactyly of
the toes [19] have been assigned to 6q15, but were only
present in one and two individuals of our cohort,
respectively.
The 6q11-q15 region contains 24 genes with a
likely clinical effect of HI based on an HI >10%
or a pLI >0.9 (supplementary Table S3). Eleven
of these likely HI genes have not been associated
with a disorder in humans so far: PTP4A1 (MIM*601585),
PHF3 (MIM*607789), SMAP1 (MIM*611372), EEF1A1
(MIM*130590), SENP6 (MIM*605003), IBTK
(MIM*606457), DOPEY1 (MIM*616823), SNAP91
(MIM*607923), CNR1 (MIM*114610), MDN1 (no MIM*
available) and BACH2 (MIM*605394). The other genes are
discussed below.
Table 3 Development for












Normal 1 1 0 0 2
Borderline 0 2 1 0 3
Mild delay 6 1 2 1 10
Moderate delay 1 4 1 1 7
Severe delay 1 1 5 0 7
Delayed but not speciﬁed 1 3 5 1 10
Unknown due to young age 1 0 2 3 6
Development categorised as normal (IQ >85), borderline (IQ 70–85), mild (IQ 50–70), moderate (IQ 30–50)
or severe (IQ <30) delay. The category with most individuals is highlighted in bold
Not speciﬁed= developmental delay is reported, but lacking sufﬁcient information to classify reliably. See
also supplementary Fig. S1
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Developmental delay
There are six genes located in 6q11-q15 that have been
associated with developmental delay (supplementary Fig.
S1). BAI3 (adhesion G protein-coupled receptor B3,
MIM*602684) was deleted in 12 individuals (11 in sub-
group A, 1 in subgroup R) and has been described as a
candidate gene for developmental delay by Vlckova et al.
[10]. Remarkably, in our cohort, developmental delay var-
ied from none to severe, when this gene was deleted. Loss-
of-function variants of KCNQ5 (potassium voltage-gated
channel subfamily Q member 5, MIM*607357) have been
linked to autosomal dominant mental retardation type 46
[20]. This gene was deleted in 24 individuals with no to
severe developmental delay (11 in subgroup A, 9 in sub-
group B, 4 in subgroup R). Three individuals have been
described in the literature with most likely loss-of-function
variants in PHIP (pleckstrin homology domain interacting
protein, MIM*612870) and a comparable phenotype con-
sisting of developmental delay, obesity and dysmorphic
features [21, 22]. In our full cohort, 25/45 patients (6 in
subgroup A, 11 in subgroup B, 2 in subgroup C and 6 in
subgroup R) had a PHIP deletion, displayed no to severe
developmental delay, and had the following features in
common with the three patients with loss-of-function var-
iants: dysplastic ears (10/16), hypotonia (15/19) and
strabism (4/12). Loss-of-function variants in SYNCRIP
(synaptotagmin-binding cytoplasmic RNA-interacting pro-
tein, MIM*616686) have been detected in individuals with
neurodevelopmental disorders and this might explain the
more severe developmental delay seen in our subgroup C
[23]. SYNCRIP was deleted in 20 individuals who almost all
had moderate to severe delay (1 in subgroup B, 7 in sub-
group C, 6 in subgroup D, 6 in subgroup R). AKIRIN2
(akirin 2, MIM*615165) has been shown to be essential for
cerebral cortex development in knockout mice [24]. No
phenotype is known in humans but six individuals in our
cohort have a deletion of this gene and moderate to severe
developmental delay. EPHA7 (ephrin receptor A7,
MIM*602190) is known to be expressed in the brain [25],
but there is no ﬁrm evidence that it is related to a
neurodevelopmental disorder and we do not see a more
severe developmental phenotype in individuals who lack
SYNCRIP, AKIRIN2 and EPHA7 (subgroups D and R)
compared to those who only lack SYNCRIP and
AKIRIN2 (subgroup C). As shown in Fig. 4 and S1, the
most important region for severe developmental delay
seems to be 6q14.2q14.3 (subgroup C) and the most
important genes involved are SYNCRIP and AKIRIN2.
However, the other genes known to be related to develop-
mental delay—BAI3, KCNQ5, PHIP and EPHA7—may
also have an effect.
Fig. 3 Age of achievement for the milestones ‘walking independently’
and ‘using two-word sentences’. The light grey bars indicate the
number of children (x axis) that have reached the milestones ‘walking
independently’ (upper panel) and ‘using two-word sentences’ (lower
panel) before the given age (y axis). The dark grey bars are the children
who were not able to perform the milestones at that age. The hatched
bars are children who were not able to perform the milestone, but who
have not yet reached the age on the y axis. For example, at age 12
years, 66–97% of the children are able to walk. Only children older
than 12 months and for whom information is available were included
here.
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As shown in Fig. S1, deletion of only PHIP or only
SYNCRIP is enough to cause severe developmental delay,
but most individuals with deletions of these genes show
borderline to severe, or mild to severe developmental delay,
respectively. On the other hand, all those with a deletion of
at least three of the six genes related to developmental delay
have mild to severe delay, so there is an indirect effect from
deletion size.
Autism
Autism spectrum disorders are frequently described in
chromosomal syndromes and an increasing number of
genes have been associated to this behavioural phenotype.
Autism-related behaviour was predominantly seen in sub-
groups C and D (Table 2 and supplementary Fig. S4).
Genes located in proximal 6q that have been linked to
autism are RIMS1 (regulating synaptic membrane exocy-
tosis 1, MIM*606629), PHIP, SYNCRIP and ZNF292 (zinc
ﬁnger protein 292, MIM*616213). A missense mutation in
RIMS1 has been identiﬁed in one family with cone-rod
dystrophy type 7, with an age of onset from 14 to 42 years
[26]. This eye disorder was not observed in our cohort.
However, others have shown an increased number of
truncating RIMS1 variants in individuals with autism
spectrum disorder [27, 28]. Thus, deletion of RIMS1 might
be a risk factor for autism. In our cohort, 22 individuals (11
in subgroup A, 8 in subgroup B, 3 in subgroup R) had a
complete or partial deletion of RIMS1. Information on
behaviour was available for 13 of them but only three had
autism-like behaviour. PHIP variants have been identiﬁed
in individuals with autism [29]. However, in our cohort,
only 3/14 individuals with a PHIP deletion had an autism
spectrum disorder. In the meta-analysis by Lelieveld et al.
[23], SYNCRIP was identiﬁed as a gene for intellectual
disability and Pinto et al. [18] described one patient with a
small de novo deletion of only 23 kb including part of the
SYNCRIP gene (see Pinto_6248_3 in Fig. 1 and S4). This
patient had severe developmental delay and autism, indi-
cating that autism may be part of the SYNCRIP-related
phenotype. In total, 7/13 patients with a SYNCRIP deletion
in our cohort had an autism spectrum disorder. There is one
report of likely disruptive variants in ZNF292 being asso-
ciated with autism [29] and we observed autism in 4/10
individuals with a ZNF292 deletion. More studies are nee-
ded to draw deﬁnite conclusions on the role of this gene in
autism.
Apart from these four known genes, the genes HTR1E (5-
hydroxytryptamine receptor 1E, MIM*182132) and HTR1B
(5-hydroxytryptamine receptor 1B MIM*182131), which did
not pass our strict HI score, may also play a role in autism-like
behaviour (supplementary Table S3 and Fig. S4). These genes
both code for serotonin receptors. Serotonin is a neuro-
transmitter that plays a role in various cognitive and beha-
vioural functions, including feeding, sleep, pain, depression
and learning [30]. A case–control study in 252 individuals
with autism spectrum disorder suggested a role for HTR1B in
the predisposition to autism, since such individuals more
often had polymorphic HTR1B variants that were known to
have a lower expression [31]. Remarkably, we observed an
autism spectrum disorder in 7/13 individuals with an HTR1E
and a SYNCRIP deletion, while the numbers were 3/13 for
RIMS1, 3/12 for HTR1B, 3/14 for PHIP and 4/10 for ZNF929
(supplementary Fig. S4).
Connective tissue-related problems
Hypermobility, foot deformities and hernias were more
often seen in subgroups A and B. COL12A1 is thought to be
responsible for these connective tissue-related problems in
the most proximal 6q deletions. Other disorders linked to
this gene are due to recessive or dominant-negative
mutations (Ullrich congenital muscular dystrophy 2
(MIM#616470) and Bethlem myopathy 2 (MIM#616471)).
If we analyse the clinical features of all the individuals in
Fig. 4 Phenotype–genotype map of proximal chromosome 6q. An
idiogram of proximal 6q is shown: genes with a known or likely
phenotypic effect and an HI score <10% or a pLI score >0.9 are shown
on the left. Genes printed in italics have a higher HI% or lower pLI,
but are discussed in the text as being related to autism. On the right-
hand side, the critical regions for various clinical features are indicated
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groups A, B and R with a COL12A1 deletion (n= 24), we
see hernias in 13/18, hyperlaxity in 15/21, foot deformities
in 8/16 and kyphosis/scoliosis in 7/12, thereby supporting
the role of this gene in the connective tissue phenotype. In
supplementary Fig. S2, we show that 14/16 individuals who
have at least two of the above features, have a deletion of
COL12A1. Another collagen gene in this region is COL9A1
(collagen type IX alpha 1 chain, MIM*120210), which is
associated with cartilage problems. However, this gene has
an HI of 24% and a pLI of 0, indicating that a HI effect is
very unlikely.
Deafness
MYO6 (myosin VI, MIM*600970) is involved in autosomal
dominant deafness type 22 (DFNA22) due to both missense
and truncating mutations [19] and thus might explain the
deafness seen in 5/23 individuals with a deletion including
MYO6. However, in DFNA22, deafness is progressive with
an age of onset of 20 years and onwards, while the indi-
viduals with hearing problems in our cohort range in age
from 8 months to 22 years, with an unknown age of onset of
their hearing loss.
Heart defects
Congenital heart defects were present in 11 patients, of
whom six had a deletion of MAP3K7, a gene known to be
related to cardiac defects, while nine had a deletion of our
candidate gene TBX18 (supplementary Fig. S3). Together
they covered the deletions of 10/11 individuals with a heart
defect. The single patient who had neither a deletion of
MAP3K7 nor TBX18 had a breakpoint 194 kb proximal to
TBX18, so a position effect cannot be excluded. MAP3K7 is
a well-known disease gene, with missense or non-truncating
mutations resulting in autosomal dominant frontometaphy-
seal dysplasia type 2 (MIM#617137) and cardiospondylo-
carpofacial (MIM#157800) syndromes, while deletions
seem to have a different phenotypic effect [32]. None-
theless, heart defects are part of the cardiospondylocarpo-
facial syndrome and we observed heart defects in 6/12
individuals with a MAP3K7 deletion. TBX18 is thought to
be responsible for the development of the myocytes in the
ventricular septum and the atrial and ventricular walls of the
heart although cardiac disease-related variants in the human
TBX18 gene have not been reported. However, hetero-
zygous variants within the TBX18 gene promoter were
reported in 4 out of 326 individuals with a ventricular septal
defect, while no functional variants were found in a control
group (n= 327) [33]. Most individuals with a heart defect
in our cohort presented with an atrial septal defect. TBX18 is
also known to be associated to congenital kidney and
urinary tract anomalies. In our total cohort (C, D, R), 19
individuals had a TBX18 deletion, of whom 6/13 had a
kidney abnormality and 9/15 had a congenital heart defect.
Limitations to our ﬁndings
Our subgroups are very small due to the rarity of chromo-
some 6 aberrations. We had detailed information for 20
participants from our Chromosome 6 Project, but the data
from the 25 case reports were often incomplete, lacking
especially information about milestones and behaviour. For
example, most of the children in our parent cohort were
described as being social, whereas this information was
often not available for the literature cases.
The main aim of the Chromosome 6 Project is to create
helpful information for parents and doctors. Here we report
the genotypes and phenotypes of 45 individuals with
proximal 6q deletions, the largest cohort to date. However,
larger numbers of cases are needed to make more detailed
and reliable descriptions of the expected phenotypes and
their variability, while follow-up data will give more insight
into their development and future perspectives. The Chro-
mosome 6 Project uses social media to collect information,
not only on the phenotypes and genotypes but also on what
topics are important for parents and how we can better
involve them in our research. The project currently has
>700 followers on Twitter and reaches >900 members of
the Facebook group. Unfortunately, we do not know how
many of these individuals have a chromosome 6 aberration.
So far, little attention has been given to the barriers that
families encounter in participating in studies like the
Chromosome 6 Project, while studies requested and initi-
ated by parents are often clinically relevant and result in
highly motivated participation. Of course, there are ques-
tions about the reliability of information retrieved directly
from parents. For example, one might assume that parents
tend to overestimate their child’s developmental level.
Therefore, we only used the results of standardised devel-
opmental tests or well-deﬁned milestones to categorise the
individuals in subgroups of developmental delay. We also
asked for formal behavioural diagnoses of autism spectrum
disorder and ADHD, rather than relying on parents’ per-
spectives of their child’s behaviour. We are in the process of
validating our online questionnaire by comparing parental
data with information collected from the medical profes-
sionals. The results so far are encouraging.
Concluding remarks
Not surprisingly, the present study showed that our ques-
tionnaire led to extra and more detailed information than
that available in case reports. We demonstrate that patient/
parent involvement via social media is a successful strategy
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and it will result in a growing wealth of information that
will prove extremely important to parents of young children
with a rare chromosome aberration. Our goal is to construct
a detailed phenotype–genotype map for the complete
chromosome 6 that can be used for counselling and the
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